GE HealthCare Technologies Inc. (NASDAQ:GEHC) Announces Quarterly Dividend of $0.04

GE HealthCare Technologies Inc. (NASDAQ:GEHC) announced a quarterly dividend on Tuesday, September 22nd. Investors of record on Friday, October 23rd will be given a dividend of 0.04 per share on Friday, November 13th. This represents a c) annualized dividend and a yield of 0.2%. The ex-dividend date is Friday, October 23rd. This is a 14.3% increase from GE HealthCare Technologies’s previous quarterly dividend of $0.04.

GE HealthCare Technologies has a dividend payout ratio of 3.0% meaning its dividend is sufficiently covered by earnings. Equities research analysts expect GE HealthCare Technologies to earn $5.41 per share next year, which means the company should continue to be able to cover its $0.14 annual dividend with an expected future payout ratio of 2.6%.

GE HealthCare Technologies Stock Down 0.2%

NASDAQ:GEHC traded down $0.17 during trading hours on Wednesday, reaching $66.11. The company had a trading volume of 224,997 shares, compared to its average volume of 4,289,888. GE HealthCare Technologies has a twelve month low of $58.75 and a twelve month high of $89.77. The company has a quick ratio of 0.97, a current ratio of 1.26 and a debt-to-equity ratio of 0.92. The firm has a market cap of $29.86 billion, a price-to-earnings ratio of 15.15, a P/E/G ratio of 1.71 and a beta of 0.70. The business’s 50-day simple moving average is $68.38 and its two-hundred day simple moving average is $67.46.

GE HealthCare Technologies (NASDAQ:GEHC) last issued its earnings results on Wednesday, July 29th. The company reported $1.13 earnings per share for the quarter, topping analysts’ consensus estimates of $1.04 by $0.09. GE HealthCare Technologies had a return on equity of 20.12% and a net margin of 9.33%.The company had revenue of $5.29 billion for the quarter, compared to analyst estimates of $5.26 billion. During the same period in the prior year, the firm earned $1.06 earnings per share. GE HealthCare Technologies’s revenue for the quarter was up 5.8% on a year-over-year basis. On average, equities analysts expect that GE HealthCare Technologies will post 4.93 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on GEHC shares. Zacks Research raised GE HealthCare Technologies from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 11th. BMO Capital Markets began coverage on GE HealthCare Technologies in a report on Wednesday, July 8th. They set a “market perform” rating and a $70.00 price target on the stock. Oppenheimer reissued an “outperform” rating on shares of GE HealthCare Technologies in a research report on Thursday, July 30th. BTIG Research restated a “buy” rating and issued a $79.00 price objective on shares of GE HealthCare Technologies in a research note on Thursday, September 17th. Finally, Royal Bank Of Canada started coverage on GE HealthCare Technologies in a research report on Tuesday, June 23rd. They set an “outperform” rating and a $80.00 target price for the company. Eleven equities research analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $78.39.

GE HealthCare Technologies Company Profile

GE HealthCare Technologies Inc is a global medical technology, pharmaceutical diagnostics and digital solutions company headquartered in Chicago, Illinois. The company provides products and services designed to support healthcare providers across diagnostic imaging, clinical care and treatment planning.

Its portfolio includes imaging systems such as magnetic resonance imaging, computed tomography, molecular imaging, X-ray and surgical imaging equipment. GE HealthCare also offers ultrasound systems, patient monitoring and care solutions, anesthesia delivery and respiratory care products, maternal and infant care technologies, and healthcare information technology.

The company’s Pharmaceutical Diagnostics business develops and supplies contrast media and radiopharmaceuticals used to enhance medical imaging and support the detection and monitoring of disease.